Septerna
Develops oral GPCR drug candidates using its Native Complex Platform.
$38.91
After-hours close+0.05 (+0.13%)
At close$38.86(−3.98%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.42 | — | — |
| Aug 2026 | −$0.43 | −$0.29 | +31.9% |
| May 2026 | −$0.51 | −$0.19 | +62.7% |
| Mar 2026 | −$0.23 | −$0.24 | −4.3% |
| Nov 2025 | $0.19 | −$0.09 | −147.4% |
The latest year is open to everyone — the 7 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Nov 2024 | — | — | — |
| Dec 2023 | |||
| Sep 2023 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 9, 2026 | −$0.42 | — | — | $20.8M | — | — |
| Aug 10, 2026 | −$0.43 | −$0.29 | +31.9% | $19.2M | $26.7M | +39.1% |
| May 12, 2026 | −$0.51 | −$0.19 | +62.7% | $17.0M | $26.5M | +56.2% |
| Mar 9, 2026 | −$0.23 | −$0.24 | −4.3% | $18.2M | $24.1M | +32.5% |
| Nov 10, 2025 | $0.19 | −$0.09 | −147.4% | $17.3M | $21.5M | +24.5% |
The latest year is open to everyone — the 7 quarters behind it read with an account. Sign in | ||||||
| Aug 11, 2025 | ||||||
| May 15, 2025 | ||||||
| Mar 27, 2025 | ||||||
| Nov 21, 2024 | ||||||
| Nov 7, 2024 | — | — | — | — | — | — |
| Dec 31, 2023 | ||||||
| Sep 30, 2023 | ||||||